Trials / Completed
CompletedNCT04596696
Evaluate Immunogenicity, Safety, and Reactogenicity of Rotavac in Healthy Infants in Vietnam
An Open Label Study to Evaluate Immunogenicity, Safety, and Reactogenicity of Rotavac® (Live Attenuated Rotavirus Vaccine) as a 3-dose Series in Healthy Infants Aged Between 6 Weeks and 8 Weeks in Vietnam
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 360 (actual)
- Sponsor
- Bharat Biotech International Limited · Industry
- Sex
- All
- Age
- 6 Weeks – 8 Weeks
- Healthy volunteers
- Accepted
Summary
An open label study to evaluate immunogenicity, safety, and reactogenicity of Rotavac® (live attenuated oral rotavirus vaccine) as a 3-dose series in healthy infants aged between 6 weeks and 8 weeks in Vietnam
Detailed description
* The study is an open labeled, clinical trial in infants 6-8 weeks of age will be assigned to receive 3 doses of Rotavac® to evaluate the immunogenicity and safety. * Active surveillance will be conducted for all participants for 14 \& 28 days after each dose of vaccine to obtain information on adverse events. ("Reactogenicity") * Childhood vaccines including pentavalent (Diptheria, Tetanus, Pertussis, Hib, Hepatitis B) and oral polio vaccine as well as injectable polio vaccine will be administered along with the study vaccines as per Expanded Program on Immunization (EPI) * Safety assessments will include observation in the study clinic for 30 minutes after each vaccine administration to record immediate adverse events. A subject diary card and personal contact with the subjects will be made to record adverse events during the 14-day period following vaccine administration.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Rotavac | Rotavac Is a monovalent vaccine containing suspension of live attenuated rotavirus 116E strain, a naturally occurring reassortant strain G9P\[11\], containing one bovine rotavirus gene P\[11\] and 10 human rotavirus genes prepared in Vero cells administered orally at 6, 10 and 14 weeks of age. |
Timeline
- Start date
- 2017-12-20
- Primary completion
- 2018-12-30
- Completion
- 2019-06-30
- First posted
- 2020-10-22
- Last updated
- 2020-10-23
Locations
1 site across 1 country: Vietnam
Source: ClinicalTrials.gov record NCT04596696. Inclusion in this directory is not an endorsement.